|Project Title||Changing Patterns of Asthma Medication use Related to U.S. Food and Drug Administration Long-Acting Beta2-agonist Regulation from 2005-2011|
Tuesday, March 1, 2016
Safety concerns associated with long-acting β2-agonists (LABAs) have led to many US Food and Drug Administration (FDA) regulatory activities for this class of drugs. Little is known about the effect of these regulatory activities on use of LABA-containing agents or other asthma medications.
long-acting beta2 agonist (LABA)
- Vaccines, Blood & Biologics
- Devices and Radiologic Health